ArticleMikrochimica acta2026
Dual colorimetric-photothermal lateral flow immunoassay based on Au@Pt nanozymes for sensitive detection of cardiac troponin I.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
A dual-signal lateral flow immunoassay (LFIA) was developed utilizing gold–platinum core–shell nanoparticles (Au@Pt NPs) for ultrasensitive cardiac troponin I (cTnI) detection. Owing to the synergistic electronic effects between the Au core and dendritic Pt shell, the Au@Pt NPs exhibit both high peroxidase-mimetic activity and a strong near-infrared photothermal effect. This allows for integrated colorimetric amplification and photothermal signal transduction within a single strip format. Under optimized conditions, the assay achieved a visual detection limit of 0.1 ng·mL⁻¹. Quantitative colorimetric determination yield limits of detection (LOD) of 0.044 ng·mL⁻¹ in PBS and 0.051 ng·mL⁻¹ in serum. Notably, the photothermal mode demonstrated exceptional matrix resilience, maintaining nearly identical LODs in PBS (0.036 ng·mL⁻¹) and serum (0.037 ng·mL⁻¹) over a linear range of 0.1–10 ng·mL⁻¹. This matrix-resilient performance is attributed to the thermophysical confinement effect of the biological matrix, which enhances the sensitivity slope in complex media. Overall, the proposed dual-mode LFIA provides a robust, pretreatment-free diagnostic tool that combines rapid visual screening with precise quantitative analysis, supporting early, point-of-care assessment of myocardial injury.
Indexed as
Identifiers
41904727What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.